Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.

MN58b is a novel anticancer drug that inhibits choline kinase, resulting in inhibition of phosphocholine synthesis. The aim of this work was to develop a noninvasive and robust pharmacodynamic biomarker for target inhibition and, potentially, tumor response following MN58b treatment. Human HT29 (colon) and MDA-MB-231 (breast) carcinoma cells were examined by proton (1H) and phosphorus (31P) magnetic resonance spectroscopy (MRS) before and after treatment with MN58b both in culture and in xenografts. An in vitro time course study of MN58b treatment was also carried out in MDA-MB-231 cells. In addition, enzymatic assays of choline kinase activity in cells were done. A decrease in phosphocholine and total choline levels (P < 0.05) was observed in vitro in both cell lines after MN58b treatment, whereas the inactive analogue ACG20b had no effect. In MDA-MB-231 cells, phosphocholine fell significantly as early as 4 hours following MN58b treatment, whereas a drop in cell number was observed at 48 hours. Significant correlation was also found between phosphocholine levels (measured by MRS) and choline kinase activities (r2 = 0.95, P = 0.0008) following MN58b treatment. Phosphomonoesters also decreased significantly (P < 0.05) in both HT29 and MDA-MB-231 xenografts with no significant changes in controls. 31P-MRS and 1H-MRS of tumor extracts showed a significant decrease in phosphocholine (P < or = 0.05). Inhibition of choline kinase by MN58b resulted in altered phospholipid metabolism both in cultured tumor cells and in vivo. Phosphocholine levels were found to correlate with choline kinase activities. The decrease in phosphocholine, total choline, and phosphomonoesters may have potential as noninvasive pharmacodynamic biomarkers for determining tumor response following treatment with choline kinase inhibitors.

[1]  J. Lacal,et al.  Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action , 2004, Oncogene.

[2]  D. Megías,et al.  Choline Kinase Activation Is a Critical Requirement for the Proliferation of Primary Human Mammary Epithelial Cells and Breast Tumor Progression , 2004, Cancer Research.

[3]  E. Eisenhauer,et al.  Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. , 2004, Journal of the National Cancer Institute.

[4]  Z. Bhujwalla,et al.  Molecular Causes of the Aberrant Choline Phospholipid Metabolism in Breast Cancer , 2004, Cancer Research.

[5]  C. Aoyama,et al.  Structure and function of choline kinase isoforms in mammalian cells. , 2004, Progress in lipid research.

[6]  A. Ramírez de Molina,et al.  From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. , 2004, Cancer letters.

[7]  J. Lacal,et al.  Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells , 2003, Oncogene.

[8]  J. Griffiths,et al.  Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. , 2003, Journal of the National Cancer Institute.

[9]  P. Workman.  How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. , 2003, Current pharmaceutical design.

[10]  P. Workman.  Challenges of PK/PD measurements in modern drug development. , 2002, European journal of cancer.

[11]  R. Rosell,et al.  Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. , 2002, Biochemical and biophysical research communications.

[12]  Jose M. Silva,et al.  Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy , 2002, Oncogene.

[13]  J. Walecki,et al.  1H-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. , 2002, International journal of radiation oncology, biology, physics.

[14]  Paul Workman,et al.  Translating basic cancer research into new cancer therapeutics. , 2002, Trends in molecular medicine.

[15]  M O Leach,et al.  Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells , 2002, British Journal of Cancer.

[16]  A. Ramírez de Molina,et al.  Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells. , 2001, Biochemical and biophysical research communications.

[17]  Lacal Jc.  Choline kinase: a novel target for antitumor drugs. , 2001 .

[18]  M. Leach,et al.  Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells , 2001, British Journal of Cancer.

[19]  J. Lacal.  Choline kinase: a novel target for antitumor drugs. , 2001, IDrugs : the investigational drugs journal.

[20]  M. Leach,et al.  Breast imaging technology: Imaging biochemistry - applications to breast cancer , 2000, Breast Cancer Research.

[21]  P. Workman,et al.  Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. , 2000, Molecular pharmacology.

[22]  J. J. Mukherjee,et al.  Expression of human choline kinase in NIH 3T3 fibroblasts increases the mitogenic potential of insulin and insulin-like growth factor I. , 2000, Cellular signalling.

[23]  P. McSheehy.  On the role of MRS in drug development , 1999, NMR in biomedicine.

[24]  A. Harris,et al.  Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? , 1999, Journal of the National Cancer Institute.

[25]  J. Lacal,et al.  In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. , 1999, Cancer research.

[26]  J. Griffiths,et al.  Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis , 1999, British Journal of Cancer.

[27]  Z. Bhujwalla,et al.  Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. , 1999, Cancer research.

[28]  T. Powles,et al.  Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment , 1998, NMR in biomedicine.

[29]  D. Vance,et al.  Biochemical and Evolutionary Significance of Phospholipid Methylation* , 1998, The Journal of Biological Chemistry.

[30]  N. J. McNally,et al.  United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). , 1998, British Journal of Cancer.

[31]  J. Lacal,et al.  Choline kinase inhibitors as a novel approach for antiproliferative drug design , 1997, Oncogene.

[32]  S. Williams,et al.  Immortalization and transformation are associated with specific alterations in choline metabolism. , 1996, Cancer research.

[33]  H. Degani,et al.  Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. , 1996, Anticancer research.

[34]  H. Degani,et al.  Simultaneous extraction of cellular lipids and water‐soluble metabolites: Evaluation by NMR spectroscopy , 1996, Magnetic resonance in medicine.

[35]  C. Kent,et al.  Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. , 1995, Archives of biochemistry and biophysics.

[36]  Z. Kiss,et al.  Wortmannin inhibits carcinogen‐stimulated phosphorylation of ethanolamine and choline , 1995, FEBS letters.

[37]  C. Kent,et al.  Eukaryotic phospholipid biosynthesis. , 1995, Annual review of biochemistry.

[38]  D. Vance,et al.  Requirement of phosphatidylcholine for normal progression through the cell cycle in C3H/10T1/2 fibroblasts. , 1994, Journal of lipid research.

[39]  Z. Darżynkiewicz,et al.  Flow cytometric detection of apoptosis: comparison of the assays of in situ DNA degradation and chromatin changes. , 1994, Cytometry.

[40]  S. Jackowski.  Coordination of membrane phospholipid synthesis with the cell cycle. , 1994, The Journal of biological chemistry.

[41]  A. Cuadrado,et al.  Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. , 1993, Oncogene.

[42]  M. Leach,et al.  Phospholipid metabolites, prognosis and proliferation in human breast carcinoma , 1993, NMR in biomedicine.

[43]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[44]  U. Klose.  In vivo proton spectroscopy in presence of eddy currents , 1990, Magnetic resonance in medicine.

[45]  J. Exton.  Signaling through phosphatidylcholine breakdown. , 1990, The Journal of biological chemistry.

[46]  C. Kent,et al.  The effect of polycyclic aromatic hydrocarbons on choline kinase activity in mouse hepatoma cells. , 1989, Biochimica et biophysica acta.

[47]  P. Luyten,et al.  Accurate quantification of in vivo 31P NMR signals using the variable projection method and prior knowledge , 1988, Magnetic resonance in medicine.

[48]  Roger J. Ordidge,et al.  Image-selected in Vivo spectroscopy (ISIS). A new technique for spatially selective nmr spectroscopy , 1986 .

[49]  Roger J. Ordidge,et al.  Image selected in-vivo spectroscopy (ISIS) , 1985 .

[50]  Hans Ulrich Bergmeyer,et al.  Methods of Enzymatic Analysis , 2019 .

[51]  S. Rose.  Transformed cells. , 1949, Scientific American.